Retraction Watch Staff
April 06, 2022
A cancer researcher faked data in a grant application, her PhD thesis, and seven published papers, according to the U.S. Office of Research Integrity.
Toni Brand, who earned her PhD from the University of Wisconsin and served as a postdoc at the University of California, San Francisco (UCSF), “engaged in research misconduct by knowingly or recklessly falsifying or fabricating western blot data, by reusing and relabeling data to represent expression of proteins in control experiments measuring the purity of cytoplasmic and nuclear cell fractionation, measurements of proteins of interest, and measurements of the same protein under different experimental conditions or loading controls,” the ORI said in a report published today.
One of Brand’s papers, published in Science Signaling, was retracted in November 2021. The notice said that the Wisconsin committee found that 11 images in the paper were “duplicated, mislabeled, or had other anomalies” but “found that these issues were due to carelessness and lack of attention to detail rather than through any intent to deceive, and thus concluded that no research misconduct was committed.”
The ORI, however, included that paper among those in which Brand “engaged in research misconduct.”
It is unclear when UCSF’s investigation wrapped up. [See update at the end of this post.] We know following a public records request that the University of Wisconsin notified Science Signaling of its findings of misconduct in August 2018 but that the journal – in what the editor called his “egregious delay” – took more than three years to retract the paper.
Brand, who “neither admits nor denies ORI’s findings of research misconduct,” agreed to have any research of hers funded by the Public Health Service – the parent agency of the NIH – supervised for four years. She also agreed to retract three additional papers:
- Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3 (PLOS ONE, 2013)
- AXL Mediates Resistance to Cetuximab Therapy (Cancer Research, 2014)
- Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer (Cancer Research, 2018)
The three papers have been cited more than 150 times in total.
Brand, now a science teacher at the Mount Tamalpais School in Mill Valley, California, did not respond to a request for comment. Paul Thaler, her attorney, declined to comment.
The finding of misconduct is the sixth of 2022 for the ORI, twice as many findings as it made all of last year.
Leave a Reply